Novo Nordisk A/S (NVO)

51.66
1.24 2.46
NYSE : Health Technology
Prev Close 50.42
Open 51.30
Day Low/High 51.11 / 51.68
52 Wk Low/High 41.23 / 52.83
Volume 1.62M
Avg Volume 1.45M
Exchange NYSE
Shares Outstanding 1.86B
Market Cap 122.54B
EPS 2.50
Div & Yield 0.88 (1.76%)

Latest News

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Daily Earnings Round-Up

Daily Earnings Round-Up

This is your round-up of the day's earnings reports

Global Financial News: Apple Takes the Steam Out of the Global Equity Rally

Global Financial News: Apple Takes the Steam Out of the Global Equity Rally

European stocks slip as Apple earnings take the steam out of the global equity rally.

Bullish and Bearish Reversals for This Week

Bullish and Bearish Reversals for This Week

Financials have moved to the bearish side, this week.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Is This a Market Top or Just Consolidation?

Is This a Market Top or Just Consolidation?

Afternoon surge is surfacing again.

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Demographic trends that boosted big gains in prior years haven't gone away.

Stop Listening to 'The Market'

Stop Listening to 'The Market'

Here are stocks with solid fundamentals at some of the best absolute entry points in years.

Novo Nordisk Is an Opportunity

Novo Nordisk Is an Opportunity

I bought the stock too early, but I am adding more.

ZBH's Big Unjustified Price Correction

ZBH's Big Unjustified Price Correction

Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

In a "take no pain, take no prisoners" market, health care stocks languish.

'Left-to-Right' Makes Might

'Left-to-Right' Makes Might

Profiting from these companies' steady long-term gains requires patience.

Novo Nordisk: Growth at a Good Price

Novo Nordisk: Growth at a Good Price

Novo is 'not yet screamingly cheap, but it is certainly approaching great value.'

Here's Why Shares of Novo Nordisk are Lower Thursday

Here's Why Shares of Novo Nordisk are Lower Thursday

Shares of Novo Nordisk were lower Thursday after announcing layoffs across its global business.

Trading Beats Buy and Hold: An Illustration

Trading Beats Buy and Hold: An Illustration

The ability to exit pricey shares with the chance to buy them back cheaper occurs with regularity.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Small biotech plunged in July, but has stabilized on two key deals.

Novo Nordisk Betting on New Long-Lasting Diabetes Drug to Dominate

Novo Nordisk Betting on New Long-Lasting Diabetes Drug to Dominate

Shares of Novo Nordisk popped 5% last week after the U.S. Food and Drug Administration (FDA) approved the application for its long-acting insulin drug Tresiba.

Quant Picks: 4 Pharmaceutical Companies to Add to Your Porfolio

Quant Picks: 4 Pharmaceutical Companies to Add to Your Porfolio

Here are some of the best pharmaceuticals our algorithm says you should consider looking at.

Grading the Daily Bull Charts for June

Overall, slightly more than half the charts scored a 'B' or better.

Obamacare Ruling Means the Debate Is Over

As health-care stocks rally, it's time for politicians to move on.

Bull Chart of the Day: Novo Nordisk

It may be late to the party, but it could still offer rewards.

For Those More Sanguine Than I

Investors without a deep-value bias might want to consider these.